Off-Label Drug Use in Oncology

Author:

Karabina E. V.1ORCID,Sakaeva D. D.2ORCID,Lipatov O. N.3ORCID

Affiliation:

1. Tula Regional Clinical Oncology Dispensary; Bashkir State Medical University

2. Bashkir State Medical University; Mother and Child Clinical Hospital

3. Bashkir State Medical University

Abstract

The off-label use of medicines is a routine clinical practice of oncology, especially in malignant-tumour patients with no treatment alternatives left when registered-drug options have been exhausted or standard therapies reveal contraindications. The recent shift from single-gene assays to multigene panels powered by full-exome or -genome sequencing expands the capacity of precision therapy, leading to a wider agnostic off-label use of targeted drugs for detecting a particular molecular genetic disorder. Studies of the off-label drug use in oncology will clarify the feasibility and safety of such prescriptions in patients with rare forms of malignancy when registered therapies have been exhausted or standard treatment reveals contraindications. This article examines the prevalence and landscape of off-label drug use in cancer patients and elaborates on the off-label principle. The paper presents a critical reflection on the off-label use of medicines in oncology.

Publisher

Bashkir State Medical University

Subject

General Engineering,Energy Engineering and Power Technology

Reference40 articles.

1. Martsevich S.Y., Navasardjan A.R., Komkova N.A. Off-label prescribing. possible causes, types and consequences. Legal regulation in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2017;13(5):667–74 (In Russ). DOI: 10.20996/1819-6446-2017-13-5-667-674

2. Bunyatyan N.D., Korobov N.V., Uteshev D.B., Yavorskiy A.N. Off-label drugs: some aspects of their use and promotion. Medical Technologies. Assessment and Choice. 2010;2:49–53 (In Russ.).

3. Pereverzev A.P., Lepakhin V.K. Off-label use of drugs — important problem of modern pharmacotherapy. Ural Medical Journal. 2013;3(108):133–6 (In Russ.).

4. Braillon A., Lexchin J. Innovation and off-label use, the French case and more. Br J Clin Pharmacol. 2019;85(10):2446–7. DOI: 10.1111/bcp.13993

5. Khadartsev A.A. Ivanov D.V., Khadartseva K.A. Legal aspects off-labeluse of drugs (literature review). Journal of New Medical Technologies. 2020;3:115–23 (In Russ.). DOI: 10.24411/2075-4094-2020-16654

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3